Stocks

Ra Pharmaceuticals, Inc. (RARX) and MabVax Therapeutics Holdings, Inc. (MBVX) Activist Update

Novo A/S has filed an SC 13D/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,531,562 shares of Ra Pharmaceuticals, Inc. (NASDAQ:RARX). This represents 4.9 percent ownership of the company. Previously, Novo A/S had reported owning 2,031,562 shares, indicating a decrease of -24.61 percent.

Hansen John David has filed an SC 13D form with the Securities and Exchange Commission (SEC) disclosing ownership of 475,972 shares of MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX). This represents 6.5 percent ownership of the company. MabVax Therapeutics Holdings, Inc. has declared a standard industrial code (sic) of 2834 which is the “Pharmaceutical Preparations” industry.

When a person or group of persons acquires beneficial ownership of more than 5% of a company’s equity securities, they are required to file a Schedule 13D or 13G with the SEC. If these groups intend to influence management into changing the business strategy, they are considered “activist” investors. There is considerable academic research that suggest activist investors contribute to excess returns in equities in the subsequent twelve months after the event.

Investors that acquire 10% or more of a company’s shares, or that gain a board seat, are considered insiders by the SEC and are subject to stricter insider trading filing requirements.

New Activist Investor Filings

Investors that acquire more than 5% of the shares of a company and intend to influence management are considered activist investors and must file a 13D.

MabVax Therapeutics Holdings, Inc. (MBVX) – Hansen John David has filed a new SC 13D, reporting a 6.50% ownership stake in MabVax Therapeutics Holdings.

RAIT Financial Trust (RFT) – Frischer Charles has filed a new SC 13D, reporting a 9.80% ownership stake in RAIT Financial Trust.

Amended Activist Investor Filings

MabVax Therapeutics Holdings, Inc. (MBVX) – Hansen John David has filed an amended Schedule 13D/A, reporting a 4.75% ownership stake in MabVax Therapeutics Holdings.

Ascendis Pharma AS (ASND) – Vivo Ventures Vii, Llc has filed an amended Schedule 13D/A, reporting a 4.30% ownership stake in Ascendis Pharma AS. This is a decrease of 37.68% from their previous filing.

Alcentra Capital Corp. (ABDC) – Stilwell Joseph has filed an amended Schedule 13D/A, reporting a 8.50% ownership stake in Alcentra Capital. This is a decrease of 39.29% from their previous filing.

Tintri, Inc. (TNTR) – Lightspeed Venture Partners Viii Lp has filed an amended Schedule 13D/A, reporting a 12.20% ownership stake in Tintri.

Tintri, Inc. (TNTR) – Silver Lake Group, L.L.C. has filed an amended Schedule 13D/A, reporting a 17.30% ownership stake in Tintri.

CCA Industries, Inc. (CAW) – Funston Lance T has filed an amended Schedule 13D/A, reporting a 0.00% ownership stake in CCA Industries. This is a decrease of 100.00% from their previous filing.

MutualFirst Financial, Inc. (MFSF) – Ancora Advisors, LLC has filed an amended Schedule 13D/A, reporting a 7.22% ownership stake in MutualFirst Financial. This is an increase of 16.45% from their previous filing.

Ra Pharmaceuticals, Inc. (RARX) – Novo A/S has filed an amended Schedule 13D/A, reporting a 4.90% ownership stake in Ra Pharmaceuticals. This is a decrease of 24.62% from their previous filing.

Forum Merger Corporation (FMCI) – Forum Investors I, Llc has filed an amended Schedule 13D/A, reporting a 0.00% ownership stake in Forum Merger.

The9 Ltd. (NCTY) – Ark Pacific Investment Management Ltd has filed an amended Schedule 13D/A, reporting a 2.80% ownership stake in The9. This is a decrease of 92.05% from their previous filing.

Entellus Medical, Inc. (ENTL) – Svlsf Iv, Llc has filed an amended Schedule 13D/A, reporting a 0.00% ownership stake in Entellus Medical. This is a decrease of 100.00% from their previous filing.

Cascadian Therapeutics, Inc. (CASC) – Growth Equity Opportunities IV, LLC has filed an amended Schedule 13D/A, reporting a 19.70% ownership stake in Cascadian Therapeutics. This is a decrease of 1.45% from their previous filing.

Lawson Products, Inc. (LAWS) – King Luther Capital Management Corp has filed an amended Schedule 13D/A, reporting a 26.20% ownership stake in Lawson Products. This is an increase of 4.38% from their previous filing.

Wowo Limited (JMU) – Maodong Xu has filed an amended Schedule 13D/A, reporting a 10.27% ownership stake in Wowo.

New Passive Investor Filings

Investors that acquire more than 5% of the shares of a company but have no intention of influencing management are considered passive investors and must file a 13G.

Forum Merger Corporation (FMCI) – Owl Creek Asset Management, L.P. has filed a new SC 13G, reporting a 7.20% ownership stake in Forum Merger.

Pfenex Inc. (PFNX) – Flynn James E has filed a new SC 13G, reporting a 5.32% ownership stake in Pfenex.

Five Point Holdings, LLC (FPH) – Marathon Asset Management Lp has filed a new SC 13G, reporting a 6.30% ownership stake in Five Point Holdings.

Greenlight Capital Re, Ltd. (GLRE) – Morgan Stanley has filed a new SC 13G, reporting a 5.00% ownership stake in Greenlight Capital Re.

Amended Passive Investor Filings

Cardiome Pharma Corp. (CRME) – Westfield Capital Management Co Lp has filed an amended Schedule 13D/A, reporting a 12.62% ownership stake in Cardiome Pharma. This is a decrease of 8.15% from their previous filing.

MagnaChip Semiconductor Corp (MX) – Evermore Global Advisors, LLC has filed an amended Schedule 13D/A, reporting a 11.10% ownership stake in MagnaChip Semiconductor. This is an increase of 12.12% from their previous filing.

Enzo Biochem, Inc. (ENZ) – Evermore Global Advisors, LLC has filed an amended Schedule 13D/A, reporting a 10.10% ownership stake in Enzo Biochem. This is an increase of 4.12% from their previous filing.

Heartland Express, Inc. (HTLD) – American Century Investment Management Inc has filed an amended Schedule 13D/A, reporting a 10.63% ownership stake in Heartland Express. This is an increase of 8.25% from their previous filing.

Fintel provides free investor tools for data driven investors. Get full coverage of Baker Brothers Advisors LP or ACRX : AcelRx Pharmaceuticals Stock Analysis and Research Report.